Search results for "LMWH"
showing 5 items of 5 documents
Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: The use of fixed sub-therap…
2012
No data are available regarding the management of cancer patients requiring interruption of long-term vitamin-K antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of low-molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at fixed subtherapeutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated 12 hr after surgery and VKA the day after. In patients receiving chem…
Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial …
2016
Summary Background Women with a history of venous thromboembolism (VTE) have a 2% to 10% absolute risk of VTE recurrence during subsequent pregnancies. Therefore, current guidelines recommend that all pregnant women with a history of VTE receive pharmacologic thromboprophylaxis. The optimal dose of low-molecular-weight heparin (LMWH) for thromboprophylaxis is unknown. In the Highlow study (NCT 01828697; www.highlowstudy.org ), we compare a fixed low dose of LMWH with an intermediate dose of LMWH for the prevention of pregnancy-associated recurrent VTE. We present the rationale and design features of this study. Methods The Highlow study is an investigator-initiated, multicentre, internation…
Comments on “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations” by D'Amato et al
2021
We have read with interest the letter from D’Amato et al. entitled “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations”....
A review of venous thromboembolism in COVID‐19: A clinical perspective
2021
Abstract Coronavirus disease‐19 (COVID‐19) started in Wuhan, China in December 2019 and spread to all around the world in a short period of time. Hospitalized patients with COVID‐19 mostly could suffer from an abnormal coagulation activation risk with increased venous thrombosis events and a poor clinical course. The reported incidence rates of thrombotic complications in hospitalized COVID‐19 patients vary between 2.6 and 85% (both in non‐critically ill and critically ill patients). The risk of venous thromboembolism is not known in non‐hospitalized patients with COVID‐19. There are numerous studies and guidelines for administration of thromboprophylaxis for COVID‐19 cases. All hospitalize…
The use of low molecular weight heparin in a Sicilian teaching hospital
2013
LMWH are replacing unfractionated heparin (UFH) for therapeutic anticoagulation owing to their more predictable pharmacokinetics and ease of use. Especially in Sicily, their prescription volume is steadily increasing in general practice, but little is known about their use in the hospital setting. We investigated LMWH use at the Policlinico Universitario P. Giaccone of Palermo by examining the records of drug dispensation to the wards in the years 2010-2012. From 2010 to 2012 the use of LMWH at Policlinico of Palermo remained stable with a mean of 71 DDD/100 bed days (range 69-73) of drugs dispensed. Enoxaparin, nadroparin and reviparin were the most prescribed molecules, accounting each on…